159 related articles for article (PubMed ID: 22695475)
1. The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
Milanović D; Braun F; Weber W; Grosu AL; Behe M; Niedermann G
BMC Cancer; 2012 Jun; 12():242. PubMed ID: 22695475
[TBL] [Abstract][Full Text] [Related]
2. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.
Dorsey JF; Mintz A; Tian X; Dowling ML; Plastaras JP; Dicker DT; Kao GD; El-Deiry WS
Mol Cancer Ther; 2009 Dec; 8(12):3285-95. PubMed ID: 19996278
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
[TBL] [Abstract][Full Text] [Related]
6. Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Baguley BC; Siemann DW
Expert Opin Investig Drugs; 2010 Nov; 19(11):1413-25. PubMed ID: 20964495
[TBL] [Abstract][Full Text] [Related]
7. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
8. TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
Hantel C; Ozimek A; Lira R; Ragazzon B; Jäckel C; Frantsev R; Reincke M; Bertherat J; Mussack T; Beuschlein F
Mol Cell Endocrinol; 2016 Mar; 423():87-95. PubMed ID: 26768118
[TBL] [Abstract][Full Text] [Related]
9. Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Corroyer-Dulmont A; Pérès EA; Petit E; Guillamo JS; Varoqueaux N; Roussel S; Toutain J; Divoux D; MacKenzie ET; Delamare J; Ibazizène M; Lecocq M; Jacobs AH; Barré L; Bernaudin M; Valable S
Neuro Oncol; 2013 Jan; 15(1):41-56. PubMed ID: 23115160
[TBL] [Abstract][Full Text] [Related]
10. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1α by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT.
Shen LF; Zhao X; Zhou SH; Lu ZJ; Zhao K; Fan J; Zhou ML
Oncotarget; 2017 May; 8(21):34709-34726. PubMed ID: 28410229
[TBL] [Abstract][Full Text] [Related]
12. PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.
Chen Y; Wang L; Liu H; Song F; Xu C; Zhang K; Chen Q; Wu S; Zhu Y; Dong Y; Zhou M; Zhang H; Tian M
Mol Imaging Biol; 2018 Apr; 20(2):309-317. PubMed ID: 28795272
[TBL] [Abstract][Full Text] [Related]
13. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
14. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
15. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Kim TJ; Ravoori M; Landen CN; Kamat AA; Han LY; Lu C; Lin YG; Merritt WM; Jennings N; Spannuth WA; Langley R; Gershenson DM; Coleman RL; Kundra V; Sood AK
Cancer Res; 2007 Oct; 67(19):9337-45. PubMed ID: 17909042
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts.
Yao D; Zhao H; Zhang F; Chen J; Jiang X; Zhu X
J Huazhong Univ Sci Technolog Med Sci; 2010 Dec; 30(6):757-61. PubMed ID: 21181367
[TBL] [Abstract][Full Text] [Related]
17. Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.
Marrero A; Becker T; Sunar U; Morgan J; Bellnier D
Photochem Photobiol; 2011; 87(4):910-9. PubMed ID: 21575001
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
[TBL] [Abstract][Full Text] [Related]
19. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
[TBL] [Abstract][Full Text] [Related]
20. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
